AR085976A1 - Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn) - Google Patents
Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn)Info
- Publication number
- AR085976A1 AR085976A1 ARP120101238A ARP120101238A AR085976A1 AR 085976 A1 AR085976 A1 AR 085976A1 AR P120101238 A ARP120101238 A AR P120101238A AR P120101238 A ARP120101238 A AR P120101238A AR 085976 A1 AR085976 A1 AR 085976A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrcrd
- group
- alkyl
- formula
- vinblastine
- Prior art date
Links
- 238000002512 chemotherapy Methods 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 229960003048 vinblastine Drugs 0.000 abstract 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
- JNAHVYVRKWKWKQ-UHFFFAOYSA-N 2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1C1(C)CCCN1 JNAHVYVRKWKWKQ-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 229960000473 altretamine Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 abstract 1
- 229950010514 misonidazole Drugs 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000624 procarbazine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960003433 thalidomide Drugs 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 1
- 229960002066 vinorelbine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Uso de un compuesto de fórmula (1) en la elaboración de un medicamento para usar en un método del tratamiento de neuropatía periférica inducida por quimioterapia en un sujeto, caracterizado porque el compuesto tiene la fórmula (1), donde R1, R2, y R3 se seleccionan en forma independiente del grupo que consiste en hidrógeno, alquenilo, alcoxilo, alcoxicarbonilo, alquilo, alquinilo, ciano, haloalcoxilo, haloalquilo, halógeno, hidroxilo, hidroxialquilo, nitro, NRARB, y (NRARB)carbonilo; A es un anillo no aromático de 4, 5, 6, 7 ú 8 miembros que contiene 1 ó 2 átomos de nitrógeno y, opcionalmente, un átomo de azufre u oxígeno, en donde el anillo no aromático se sustituye opcionalmente con 1, 2, ó 3 sustituyentes que se eligen del grupo que consiste en alquenilo, alcoxilo, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, ciano, haloalcoxilo, haloalquilo, halógeno, heterociclo, heterocicloalquilo, heteroarilo, heteroarilalquilo, hidroxilo, hidroxialquilo, nitro, NRCRD, (NRCRD)alquilo, (NRCRD)carbonilo, (NRCRD)carbonilalquilo, (NRCRD)sulfonilo, y oxo; y RA, RB, RC, y RD se seleccionan en forma independiente del grupo que consiste en hidrógeno, alquilo, y alquilcarbonilo; o una sal o solvato farmacéuticamente aceptable de los mismos.Reivindicación 3: El uso de las reivindicaciones 1 ó 2, caracterizado porque A se elige del grupo que consiste en los compuestos de formula (2) y (3). Reivindicación 5: El uso de cualquiera de las reivindicaciones 1 a 4, caracterizado porque el compuesto de fórmula (1) es 2-(2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida. Reivindicación 8: El uso de cualquiera de las reivindicaciones 1 a 7, caracterizado porque dicho tratamiento además comprende la administración de uno o más agentes quimioterapéuticos. Reivindicación 10: El uso de las reivindicaciones 8 ó 9, caracterizado porque el agente quimioterapéutico se elige del grupo que consiste en bortezomib, carboplatino, cisplatino, gemcitabina, misonidazol, oxaliplatino, procarbazina, talidomida, docetaxel, hexametilmelamina, paclitaxel, vincristina, vinblastina, o vinorelbina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473970P | 2011-04-11 | 2011-04-11 | |
| US201161476616P | 2011-04-18 | 2011-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085976A1 true AR085976A1 (es) | 2013-11-06 |
Family
ID=45976523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101238A AR085976A1 (es) | 2011-04-11 | 2012-04-11 | Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20120258180A1 (es) |
| EP (1) | EP2696870A1 (es) |
| JP (1) | JP2014510787A (es) |
| CN (1) | CN103687597A (es) |
| AR (1) | AR085976A1 (es) |
| AU (1) | AU2012243132A1 (es) |
| BR (1) | BR112013026327A2 (es) |
| CA (1) | CA2832817A1 (es) |
| CL (1) | CL2013002908A1 (es) |
| DO (1) | DOP2013000236A (es) |
| IL (1) | IL228719A0 (es) |
| MX (1) | MX2013011932A (es) |
| NZ (1) | NZ616227A (es) |
| RU (1) | RU2013150102A (es) |
| SG (2) | SG2014014294A (es) |
| TW (1) | TW201244714A (es) |
| WO (1) | WO2012141990A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| US20140287021A1 (en) * | 2013-03-21 | 2014-09-25 | Panacea Pharmaceuticals | Treatment of chemotherapy-induced peripheral neuropathy |
| US20160151339A1 (en) * | 2013-03-21 | 2016-06-02 | Hossein A. Ghanbari | Treatment for Chemotherapy-Induced Peripheral Neuropathy |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| RU2770307C2 (ru) * | 2017-03-31 | 2022-04-15 | Торэй Индастриз, Инк. | Терапевтическое или профилактическое средство против периферических невропатий |
| EP3765613A1 (en) | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| CN113574171A (zh) * | 2018-11-08 | 2021-10-29 | In8生物股份有限公司 | 治疗癌症的组合物和方法 |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| US20240189230A1 (en) * | 2019-08-13 | 2024-06-13 | Peptinovo Biopharma Inc. | Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20240024282A1 (en) * | 2020-09-22 | 2024-01-25 | Consuelo SAN GABRIEL ALCOLEA | C-phycocyanin for use in the treatment and/or prevention of peripheral neuropathy |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841771A4 (en) * | 2005-01-19 | 2008-09-24 | Mgi Gp Inc | COMPOUNDS OF DIAZABENZO [DE] ANTHRACENE-3-ONE AND USE IN INHIBITION OF PARP |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| CN101370497B (zh) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
| MY165570A (en) | 2006-12-28 | 2018-04-05 | Abbvie Inc | Inhibitors of poly (adp-ribose) polymerase |
| JP5439380B2 (ja) * | 2007-10-03 | 2014-03-12 | エーザイ インク． | Ｐａｒｐ阻害化合物、組成物及び使用方法 |
| CA2696423A1 (en) * | 2007-10-12 | 2009-04-16 | Guidong Zhu | 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
-
2012
- 2012-04-09 EP EP12715262.7A patent/EP2696870A1/en not_active Withdrawn
- 2012-04-09 BR BR112013026327A patent/BR112013026327A2/pt not_active IP Right Cessation
- 2012-04-09 MX MX2013011932A patent/MX2013011932A/es not_active Application Discontinuation
- 2012-04-09 CN CN201280028608.4A patent/CN103687597A/zh active Pending
- 2012-04-09 AU AU2012243132A patent/AU2012243132A1/en not_active Abandoned
- 2012-04-09 SG SG2014014294A patent/SG2014014294A/en unknown
- 2012-04-09 CA CA2832817A patent/CA2832817A1/en not_active Abandoned
- 2012-04-09 US US13/442,294 patent/US20120258180A1/en not_active Abandoned
- 2012-04-09 WO PCT/US2012/032724 patent/WO2012141990A1/en not_active Ceased
- 2012-04-09 RU RU2013150102/15A patent/RU2013150102A/ru not_active Application Discontinuation
- 2012-04-09 TW TW101112503A patent/TW201244714A/zh unknown
- 2012-04-09 JP JP2014505198A patent/JP2014510787A/ja active Pending
- 2012-04-09 SG SG2013075098A patent/SG194138A1/en unknown
- 2012-04-09 NZ NZ616227A patent/NZ616227A/en not_active IP Right Cessation
- 2012-04-11 AR ARP120101238A patent/AR085976A1/es unknown
-
2013
- 2013-10-03 IL IL228719A patent/IL228719A0/en unknown
- 2013-10-10 DO DO2013000236A patent/DOP2013000236A/es unknown
- 2013-10-10 CL CL2013002908A patent/CL2013002908A1/es unknown
- 2013-12-05 US US14/098,128 patent/US20140093585A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG194138A1 (en) | 2013-11-29 |
| DOP2013000236A (es) | 2014-01-15 |
| TW201244714A (en) | 2012-11-16 |
| CN103687597A (zh) | 2014-03-26 |
| IL228719A0 (en) | 2013-12-31 |
| JP2014510787A (ja) | 2014-05-01 |
| US20140093585A1 (en) | 2014-04-03 |
| BR112013026327A2 (pt) | 2019-09-24 |
| US20120258180A1 (en) | 2012-10-11 |
| NZ616227A (en) | 2016-01-29 |
| CL2013002908A1 (es) | 2013-12-06 |
| MX2013011932A (es) | 2013-11-01 |
| RU2013150102A (ru) | 2015-05-20 |
| EP2696870A1 (en) | 2014-02-19 |
| SG2014014294A (en) | 2014-06-27 |
| CA2832817A1 (en) | 2012-10-18 |
| AU2012243132A1 (en) | 2013-10-24 |
| WO2012141990A1 (en) | 2012-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085976A1 (es) | Inhibidores de la poli(adp-ribosa)polimerasa (parp) para el tratamiento de neuropatia periferica inducida por un quimioterapia (cipn) | |
| AR089527A1 (es) | Inhibidores de bromodominios | |
| CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
| MX2012015120A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica. | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| ES2571488T3 (es) | Compuesto heterocíclico fusionado y uso del mismo para el control de plagas | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
| PE20161035A1 (es) | Compuestos y usos de estos para la modulacion de la hemoglobina | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| PE20190805A1 (es) | Compuesto de piridina | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |